The new oral anticoagulants.
Department of Thrombosis and Vascular Biology, Rayne Institute, St Thomas' Hospital, London. karen.breen@gstt.nhs.uk
K A
KA
Breen
B J
BJ
Hunt
D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D001562:Benzimidazoles / Q000493:pharmacokinetics / Q000494:pharmacology; D017326:Clinical Trials, Phase III as Topic; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000493:pharmacokinetics / Q000494:pharmacology; D011720:Pyrazoles / Q000493:pharmacokinetics / Q000494:pharmacology; D011725:Pyridines / Q000493:pharmacokinetics / Q000494:pharmacology; D011728:Pyridones / Q000493:pharmacokinetics / Q000494:pharmacology; D000069552:Rivaroxaban; D013844:Thiazoles / Q000493:pharmacokinetics / Q000494:pharmacology; D013876:Thiophenes / Q000493:pharmacokinetics / Q000494:pharmacology
D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; D013876:Thiophenes; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran; C552171:edoxaban